Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $55.06 Consensus Target Price from Analysts

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has earned an average recommendation of “Moderate Buy” from the seventeen brokerages that are currently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation, thirteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $55.06.

A number of research analysts have weighed in on the stock. BTIG Research assumed coverage on shares of Kymera Therapeutics in a research note on Tuesday, December 10th. They issued a “buy” rating and a $60.00 price objective on the stock. Truist Financial reaffirmed a “buy” rating and issued a $53.00 price objective (down from $54.00) on shares of Kymera Therapeutics in a research note on Friday, November 1st. Wells Fargo & Company raised shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $38.00 to $57.00 in a research report on Monday, December 2nd. Leerink Partners reissued an “outperform” rating and set a $60.00 price target on shares of Kymera Therapeutics in a research report on Friday, December 27th. Finally, UBS Group dropped their price target on shares of Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a research report on Monday, November 4th.

Insider Buying and Selling

In related news, insider Ellen Chiniara sold 3,129 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $41.75, for a total transaction of $130,635.75. Following the completion of the sale, the insider now owns 54,826 shares in the company, valued at approximately $2,288,985.50. This trade represents a 5.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 15.82% of the stock is currently owned by corporate insiders.

Institutional Trading of Kymera Therapeutics

A number of large investors have recently added to or reduced their stakes in KYMR. Massachusetts Financial Services Co. MA increased its stake in shares of Kymera Therapeutics by 11.7% in the third quarter. Massachusetts Financial Services Co. MA now owns 453,377 shares of the company’s stock worth $21,458,000 after purchasing an additional 47,507 shares in the last quarter. Eventide Asset Management LLC increased its stake in shares of Kymera Therapeutics by 9.9% in the third quarter. Eventide Asset Management LLC now owns 507,902 shares of the company’s stock worth $24,039,000 after purchasing an additional 45,803 shares in the last quarter. Intech Investment Management LLC purchased a new position in shares of Kymera Therapeutics in the third quarter worth about $650,000. JPMorgan Chase & Co. increased its stake in shares of Kymera Therapeutics by 212.6% in the third quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company’s stock worth $6,649,000 after purchasing an additional 95,547 shares in the last quarter. Finally, Natixis Advisors LLC bought a new position in shares of Kymera Therapeutics in the third quarter valued at approximately $681,000.

Kymera Therapeutics Trading Up 1.4 %

Kymera Therapeutics stock opened at $37.65 on Monday. Kymera Therapeutics has a 1-year low of $29.24 and a 1-year high of $53.27. The firm has a market capitalization of $2.44 billion, a price-to-earnings ratio of -16.09 and a beta of 2.18. The firm’s fifty day moving average price is $39.97 and its two-hundred day moving average price is $44.09.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.